natgillin/translations-raw huggingface dataset:
Plasma concentrations of atorvastatin, pitavastatin, fluvastatin, pravastatin or rosuvastatin are expected to increase when co-administered with atazanavir/cobicistat or darunavir/cobicistat.
Pričakuje se, da se bodo plazemske koncentracije atorvastatina, pitavastatina, fluvastatina, pravastatina ali rosuvastatina pri sočasni uporabi z atazanavirjem/kobicistatom ali darunavirjem/kobicistatom zvišale.
Plasma concentrations of bosentan metabolites increased about 2-fold in these patients as compared to subjects with normal renal function.
Pri teh bolnikih so se plazemske koncentracije presnovkov bosentana povišale za približno 2-krat v primerjavi z osebami z normalnim ledvičnim delovanjem.
Plasma concentrations of dabigatran showed a biexponential decline with a mean terminal half-life of 11 hours in healthy elderly subjects.
Plazemska koncentracija dabigatrana se manjša dvoeksponentno s srednjo končno razpolovno dobo 11 ur pri zdravih starejših prostovoljcih.
Plasma concentrations of dabigatran showed a biexponential decline with a mean terminal half-life of 11 hours in healthy elderly subjects.
Plazemska koncentracija dabigatrana se manjša dvoeksponentno s srednjo končno razpolovno dobo 11 ur pri zdravih, starejših preizkušancih.
Plasma concentrations of digoxin
digoksina v plazmi lahko povečajo.
Plasma concentrations of DM1 and DM1-containing catabolites (Lys-MCC-DM1 and MCC-DM1) were low and comparable between patients with and without hepatic impairment.
Plazemske koncentracije DM1 in DM1 vsebujočih presnovkov (Lys-MCC-DM1 in MCC-DM1) so bile nizke in primerljive med bolniki z jetrno okvaro ali brez nje.
Plasma concentrations of elvitegravir are not expected to change upon co-administration of OATP substrates/inhibitors.
Ne pričakuje se, da bi sočasno dajanje substratov/zaviralcev OATP spremenilo koncentracije elvitegravirja v plazmi.
Plasma concentrations of linagliptin decline in a triphasic manner with a long terminal half-life (terminal half-life for linagliptin more than 100 hours), that is mostly related to the saturable, tight binding of linagliptin to DPP-4 and does not contribute to the accumulation of the drug.
Plazemska koncentracija linagliptina se manjša v treh fazah in z dolgim končnim razpolovnim časom (ki za to zdravilo znaša več kot 100 ur), ki je pretežno posledica nasičene, tesne vezave linagliptina na DPP-4 in ne povečuje kopičenja zdravila.
Plasma concentrations of lopinavir were measured over four 12-hour periods during second trimester (20-24 weeks gestation), third trimester before dose increase (30 weeks gestation), third trimester after dose increase (32 weeks gestation), and at 8 weeks post-partum.
Plazemske koncentracije lopinavirja so bile izmerjene v štirih 12- urih obdobjih med drugim trimesečjem (20 – 24 tednov gestacijske dobe), tretjim trimesečjem pred povečanjem odmerka (30 tednov gestacijske dobe), tretjim trimesečjem po povečanju odmerka (32 tednov gestacijske dobe) in pri 8 tednih po porodu.
Plasma concentrations of lopinavir were measured over four 12-hour periods during second trimester (20-24 weeks gestation), third trimester before dose increase (30 weeks gestation), third trimester after dose increase (32 weeks gestation), and at 8 weeks post-partum.
Plazemske koncentracije lopinavirja so bile izmerjene v štirih 12-urih obdobjih med drugim trimesečjem (20 – 24 tednov gestacijske dobe), tretjim trimesečjem pred povečanjem odmerka (30 tednov gestacijske dobe), tretjim trimesečjem po povečanju odmerka (32 tednov gestacijske dobe) in pri 8 tednih po porodu.
plasma concentrations of midazolam are
plazemskih koncentracij peroralnega
Plasma concentrations of OATP substrates are not expected to change upon co-administration of elvitegravir.
Ne pričakuje se, da bi sočasno dajanje elvitegravirja spremenilo koncentracije substratov OATP v plazmi.
Plasma concentrations of pitavastatin may be increased if co-administered with EVOTAZ.
Pri sočasni uporabi zdravila EVOTAZ se koncentracije pitavastatina v plazmi lahko povečajo.
Plasma concentrations of quinidine increased 20-30% when memantine was added.
Ob dodajanju memantina se je koncentracija kinidina v plazmi povečala za 20–30 %.
Plasma concentrations of telmisartan are generally 2 – 3 times higher in females than in males.
Koncentracije telmisartana v plazmi so pri ženskah večinoma 2- do 3-krat večje kot pri moških.
Plasma concentrations of the S-enantiomer are much higher than those of the R-enantiomer, which reflects a rapid chiral inversion of the R- to the S-form in a proportion similar to adults (about 60%).
Plazemske koncentracije S-enantiomer so mnogo višje od koncentracij R–enantiomer, kar kaže na hitro kiralno inverzijo R- v S- obliko, v podobnem razmerju kot pri odraslih (okrog 60 %).
Plasma concentrations of this metabolite are approximately 40 % of those seen for sildenafil.
Koncentracija tega presnovka v plazmi je približno 40 % koncentracije sildenafila.
Plasma concentrations of trazodone
(sakvinavir/ritonavir)
Plasma concentrations of trazodone may be increased when co-administered with cobicistat.
Pri sočasnem jemanju s kobicistatom se lahko koncentracije trazodona v plazmi zvišajo.
Plasma concentrations of trazodone may be increased when co-administered with EVOTAZ.
Pri sočasni uporabi zdravila EVOTAZ se koncentracije trazodona v plazmi lahko povečajo.
Plasma concentrations that are well tolerated in animals exceed at least 62-fold (Cmax) and 104-fold (Cavg) the plasma concentrations in paediatric SJIA patients, treated with up to 4 mg/kg via the subcutaneous route every 4 weeks.
Koncentracije zdravila v plazmi, ki so jih živali dobro prenašale, so najmanj 62-krat (Cmax) oziroma 104-krat (Cpovp) presegale koncentracije zdravila pri pediatričnih bolnikih s SJIA, ki so jih zdravili z odmerki kanakinumaba do 4 mg/kg subkutano vsake 4 tedne.
Plasma concentrations were below 1 ng/ml (limit of quantification) by approximately 33 days following topical administration.
Plazemske koncentracije so bile pod 1 ng/ml (meja kvantifikacije) približno 33 dni po nanosu.
plasma concentrations which may
povečanje koncentracij nevirapina v
Plasma concentrations ↑ Cortisol levels ↓ 86%
koncentracija kortizola ↓ 86
Plasma concentrations ↑ Cortisol levels ↓ 86%
koncentracija v plazmi ↑
plasma concentrations.
plazemske koncentracije navedenih zdravil
plasma concentrations.
plazemske koncentracije teh
plasma concentrations.
plazemsko koncentracijo navedenih
Plasma CPK should be measured at baseline and at regular intervals (at least once weekly) during therapy in all patients.
Raven CPK v plazmi je treba pri vseh bolnikih izmeriti pred začetkom zdravljenja kot izhodiščno vrednost in nato med zdravljenjem izvajati meritve v rednih intervalih (vsaj enkrat tedensko).
Plasma creatinine levels may rise initially due to inhibition of the renal tubular excretion of creatinine and are not necessarily indicative of a deterioration in renal function. .
Uvodoma se lahko zaradi zavrtja ledvičnega tubularnega izločanja kreatinina koncentracija kreatinina v plazmi poveča, vendar to ne pomeni nujno poslabšanja delovanja ledvic.
Plasma creatinine values should be measured prior to and 7 days after initiation of dronedarone.
Kreatinin v plazmi je treba izmeriti pred uvedbo dronedarona in 7 dni po njegovi uvedbi.
Plasma drotrecogin alfa (activated) steady-state concentrations are proportional to the infusion rate over a range of infusion rates from 12 g/kg/hr to 48 g/kg/hr.
Plazemske koncentracije drotrekogina alfa (aktiviranega) v ravnovesnem stanju so sorazmerne hitrosti infuzije v razponu hitrosti infuzije od 12 g/kg/h do 48 g/kg/h.
Plasma elimination half-life mean values ranged from approximately 5–6 hours for verteporfin.
Povprečni razpolovni čas odstranjevanja iz plazme za verteporfin je bil približno 5–6 ur.
Plasma eltrombopag apparent clearance following oral administration (CL/F) increased with increasing body weight.
Navidezni očistek eltrombopaga iz plazme (CL/F) po peroralnem odmerjanju se je povečeval z večjo telesno maso bolnikov.
Plasma eltrombopag Cmax and AUC(0-) estimates for patients with HCV enrolled in the Phase 3 studies are presented for each dose studied in Table 9.
Ocene Cmax in AUC(0-) plazemskega eltrombopaga za bolnike s HCV vključene v Fazo 3 študij so predstavljene za vsak odmerek v preglednici 9.
Plasma eltrombopag concentration-time data collected in 590 subjects with HCV enrolled in Phase III studies TPL103922/ENABLE 1 and TPL108390/ENABLE 2 were combined with data from patients with HCV enrolled in the Phase II study TPL102357 and healthy adult subjects in a population PK analysis.
Zbrani podatki koncentracija-čas plazemskega eltrombopaga pri 590 bolnikih s HCV vključenih v Fazo III študije TPL103922/ENABLE 1 in TPL108390/ENABLE 2 so bili združeni s podatki bolnikov s HCV, ki so bili vključeni v Fazo II študije PL102357 in zdravih odraslih osebah iz farmakokinetične analize populacije.
Plasma exposure (AUC and Cmax) to valdecoxib was increased (38% and 24%, respectively) when co- administered with ketoconazole (CYP3A4 inhibitor), however, a dosage adjustment should not generally be necessary for patients receiving ketoconazole.
Plazemska izpostavljenost (AUC in Cmax) valdekoksibu se je med sočasno uporabo ketokonazola (zaviralca CYP3A4) povečala (AUC za 38 % in Cmax za 24 %), vendar bolnikom, ki prejemajo ketokonazol, odmerka praviloma ni treba prilagajati.
Plasma exposure (AUC and Cmax) to valdecoxib was increased (62% and 19%, respectively) when co- administered with fluconazole (predominantly a CYP2C9 inhibitor), indicating that the dose of parecoxib should be reduced in those patients who are receiving fluconazole therapy.
Plazemska izpostavljenost (AUC in Cmax) valdekoksibu se je med sočasno uporabo flukonazola (ki zavira predvsem CYP2C9) povečala (AUC za 62 % in Cmax za 19 %); kar kaže, da je treba pri bolnikih, ki dobivajo flukonazol, odmerek parekoksiba zmanjšati.
Plasma exposure (AUCτ,ss) was increased by 26% for a 42 kg patient (2.5th percentile) and decreased by 22% for a 95 kg patient (97.5th percentile) relative to a patient weighing 62 kg (median body weight of patients in the overall patient population).
Plazemska izpostavljenost (AUCτ,ss) se je v primerjavi z bolnikom s telesno maso 62 kg (mediana telesna masa celotne populacije bolnikov) pri bolniku s telesno maso 42 kg (percentil 2,5) povečala za 26%, pri bolniku s telesno maso 95 kg (percentil 97,5) pa zmanjšala za 22%.
Plasma exposure of simeprevir (AUC) in HCV infected patients was about 2- to 3-fold higher compared to that observed in healthy subjects.
Izpostavljenost simeprevirju v plazmi (AUC) je bila pri bolnikih, okuženih s HCV; približno 2- do 3-krat večja kot pri zdravih osebah.
Plasma glucose reductions at the end of the trial with Toujeo were similar to insulin glargine 100 units/ml with a more gradual reduction during the titration period with Toujeo.
Znižanja glukoze v plazmi so bila na koncu preskušanja z zdravilom Toujeo podobna kot z insulinom glarginom 100 enot/ml, a s postopnejšim zniževanjem med obdobjem titriranja zdravila Toujeo.
Plasma HCV -RNA is measured with a research-based quantitative polymerase chain reaction assay by a central laboratory
Plazemska vrednost HCV-RNA je bila izmerjena s raziskovalnim kvantitativnim testom polimerazne verižne reakcije v centralnem laboratoriju.
Plasma HCV-RNA is measured with a research-based quantitative polymerase chain reaction assay by a central laboratory
Plazemska vrednost HCV-RNA je bila izmerjena s študijskim kvantitativnim testom verižne reakcije s polimerazo v centralnem laboratoriju.
Plasma HIV-1 RNA (log10 copies/ml), mean [range]
HIV-1 RNA v plazmi (log10 kopij/ml), povprečje
Plasma HIV-1 RNA (log10 copies/ml), mean [range] 4.3 [2.7 - 6]
HIV-1 RNA v plazmi (log10 kopij/ml), povprečje [interval] 4,3 [2,7 - 6]
Plasma HIV-1 RNA (log10 copies/ml), mean [range] 4.3 [2.7 - 6]
HIV-RNA > 100.000 kopij/ml
Plasma HIV-1 RNA (log10 copies/ml), mean [range] 4.3 [2.7 – 6]
HIV-1 RNA v plazmi (log10 kopij/ml), povprečje [razpon] 4,3 [2,7 – 6]
Plasma HIV-1 RNA below 400 copies/ml (%)
400 kopij/ml (%)
Plasma level monitoring in a Phase III clinical study showed that levels of total silodosin after 4 weeks of treatment did not change in patients with mild impairment (n=70), compared to patients with normal renal function (n=155), while the levels were doubled on average in patients with moderate impairment (n=7).
Spremljanje plazemskih ravni v klinični študiji faze III je pokazalo, da se ravni celokupnega silodozina po 4 tednih zdravljenja pri bolnikih z blago okvarjenim delovanjem (n=70) v primerjavi z bolniki z normalnim delovanjem ledvic (n=155) niso spremenile, pri bolnikih z zmerno okvarjenim delovanjem (n=7) pa so bile v povprečju podvojene.
Plasma levels increase linearly with the dose and the pharmacokinetic profile is dose-independent.
Koncentracija v plazmi narašča linearno z odmerkom in farmakokinetični profil je neodvisen od odmerka.
plasma levels is not known.
plazmi ni znan.
Plasma levels of 3- OMD were markedly and dose-dependently decreased by tolcapone when given with levodopa/AADC-I (aromatic amino acid decarboxylase - inhibitor) (benserazide or carbidopa).
Tolkapon je znatno in od odmerka odvisno znižal plazemske vrednosti 3- OMD, kadar se je dajal skupaj z levodopo/AADC-I (zaviralcem aromatske aminokislinske dekarboksilaze) (benserazidom ali karbidopo).
Plasma levels of certain anti- epileptic drugs, such as phenytoin and carbamazepine, may be increased by co-administration with Clomicalm.
Clomicalm poviša plazemske vrednosti nekaterih antiepileptikov, kot sta fenitoin in karbamazepin.
Plasma levels of certain anti- epileptic drugs, such as phenytoin and carbamazepine, may be increased by coadministration with Clomicalm.
Clomicalm poviša plazemske vrednosti nekaterih antiepileptikov, kot sta fenitoin in karbamazepin.
Plasma levels of doxorubicin and its metabolite, doxorubicinol, may be increased when doxorubicin is administered with cyclosporin, verapamil, paclitaxel or other agents that inhibit P-glycoprotein (P-Gp).
Koncentracije doksorubicina in njegovega presnovka doksorubicinola v plazmi se lahko povišajo, kadar doksorubicin dajemo skupaj s ciklosporinom, verapamilom, paklitakselom ali drugo učinkovino, ki zavira P-glikoprotein (P-Gp).
Plasma levels of efavirenz can be reduced by concomitant use of St. John’s wort due to induction of drug metabolising enzymes and/or transport proteins by St. John’s wort.
Sočasna uporaba šentjanževke lahko zmanjša koncentracije efavirenza v plazmi zaradi indukcije presnovnih encimov in/ali transportnih proteinov.
Plasma levels of efavirenz can be reduced by concomitant use of St. John’s wort due to induction of drug metabolising enzymes and/or transport proteins by St. John’s wort.
Sočasna uporaba šentjanževke lahko zmanjša koncentracije efavirenza v plazmi, ker šentjanževka inducira encime, ki presnavljajo zdravilo in/ali transportne proteine.
Plasma levels of efavirenz can be reduced by concomitant use of St. John’s wort due to induction of drug-metabolising enzymes and/or transport proteins by St. John’s wort.
Sočasna uporaba šentjanževke lahko zmanjša koncentracije efavirenza v plazmi, ker šentjanževka inducira encime, ki presnavljajo zdravilo in/ali transportne proteine.
plasma levels of methadone and
metadona v plazmi in znake
plasma levels of methadone and
nezadostnem delovanju
Plasma levels of nelfinavir can be reduced by concomitant use of the herbal preparation St. John’s wort (Hypericum perforatum).
Pri sočasni uporabi pripravka rastlinskega izvora, ki vsebuje šentjanževko (Hypericum perforatum) in nelfinavirja se lahko zmanjšajo koncentracije nelfinavirja v plazmi.
Plasma levels of nelfinavir, which is metabolised predominantly by CYP2C19 and only partially by CYP3A4, are not greatly increased by co-administration with ritonavir, and therefore nelfinavir does not require co-administration with low-dose ritonavir..
Koncentracije nelfinavirja v plazmi, ki se pretežno presnavlja s CYP2C19 in le delno s CYP3A4, niso močno povišane ob sočasnem jemanju z ritonavirjem in zato sočasno jemanje nelfinavirja z majhnimi odmerki ritonavirja ni potrebno.
Plasma levels of the acid metabolite are approximately 100-fold greater than those of the alcohol metabolite and the unchanged active substance following inhalation.
Koncentracije kislinskega presnovka v plazmi so približno 100-krat večje kot koncentracije alkoholnega presnovka in koncentracije nespremenjene zdravilne učinkovine po inhalaciji.
Plasma levels of these metabolites detected after administration of Fortacin in clinical trials were low in both male and female subjects, even after doses of it many times in excess of the clinical dose were applied.
Ravni teh presnovkov v plazmi, zaznanih po nanosu zdravila Fortacin v kliničnih preskušanjih, so bile nizke pri moških in tudi ženskih preiskovancih celo pri nanosu odmerkov, veliko večjih od kliničnega.
Plasma levels of unboosted saquinavir can be reduced by concomitant use of the herbal preparation St. John’s wort (Hypericum perforatum).
Plazemske koncentracije sakvinavirja brez podporne terapije lahko sočasna uporaba pripravka rastlinskega izvora s šentjanževko (Hypericum perforatum) zniža.
Plasma levels readily declined with mean t½ values ranging from 4.6 to 5.7 hours on day 1 and from 5.1 to 10.1 hours on day 21.
Stopnje v plazmi so hitro padale s povprečnimi vrednostmi t½, ki so 1. dan segale od 4,6 do 5,7 ure in 21. dan od 5,1 do 10,1 ure.
Plasma migalastat exposure (AUC0-∞) and Cmax demonstrated dose-proportional increases at migalastat oral doses from 50 mg to 1,250 mg.
Plazemska izpostavljenost migalastatu (AUC0-∞) in Cmax sta pri peroralnih odmerkih migalastata od 50 mg do 1 250 mg pokazala odmerku sorazmeren porast.
Plasma pharmacokinetic profiles were analysed on day 1 and on either day 7 or day 28, by which time plasma concentrations had reached steady state.
Plazemski farmakokinetični profili so bili analizirani 1. dne, nato pa bodisi 7. bodisi 28. dne, ko so plazemske koncentracije že dosegle stanje dinamičnega ravnovesja.
Plasma pharmacokinetics of dexmedetomidine is similar in the ICU population following infusion >24 h.
Plazemska farmakokinetika deksmedetomidina je podobna pri populaciji bolnikov z oddelkov za intenzivno nego po infundiranju >24 ur.
Plasma potassium should be measured in patients at risk before starting heparin therapy and monitored regularly thereafter particularly if treatment is prolonged beyond about 7 days.
Pri ogroženih bolnikih je treba pred začetkom zdravljenja s heparinom izmeriti kalij v plazmi in ga nato redno nadzirati, zlasti če zdravljenje traja več kot približno 7 dni.
Plasma protein binding
Vzdrževalno zdravljenje:
Plasma protein binding could not be measured due to instability, but based on the physicochemical properties of osimertinib plasma protein binding is likely to be high.
Vezave na beljakovine v plazmi ni bilo mogoče meriti zaradi nestabilnosti, toda glede na fizikalno-kemijske lastnosti osimertiniba je njegova vezava na beljakovine v plazmi verjetno visoka.
Plasma protein binding following a single oral dose of 14C-labelled rasagiline is approximately 60 to 70%.
Plazemska proteinska vezava, ki sledi enojnemu odmerku s C-označenim razagilinom, je približno 60 do 70 %.
Plasma protein binding in humans is approximately 87%.
Vezava na plazemske proteine pri človeku je približno 87 %.
Plasma protein binding is 30 to 40%.
Vezava kalcitonina na plazemske proteine je 30 %–40 %.
Plasma protein binding is approximately 96 %, with negligible binding to cellular blood components.
Vezava na plazemske beljakovine je približno 96 %, z zanemarljivo v1e4zavo na krvne celice.
Plasma protein binding is at 85-87 %.
Vezava na plazemske proteine je okoli 85 –87 %.
Plasma protein binding is high (>96%).
Vezava na beljakovine v plazmi je visoka (> 96%).
Plasma protein binding of brinzolamide is moderate (about 60%).
Brinzolamid se zmerno veže na plazemske proteine (približno 60%).
Plasma protein binding of cladribine is 25% on average, with a wide interindividual variation (5-50%).
Plazemska vezava kladribina na beljakovine je povprečno 25 % s širokim razponom razlikovanja med posamezniki (5–50 %).
Plasma protein binding of irbesartan is approximately 96 %, with negligible binding to cellular blood components.
Na plazemske beljakovine se veže približno 96 % irbesartana, na celične sestavine krvi pa zanemarljivo malo.
Plasma protein binding of linagliptin is concentration-dependent, decreasing from about 99% at 1 nmol/l to 75-89% at ≥ 30 nmol/l, reflecting saturation of binding to DPP-4 with increasing concentration of linagliptin At high concentrations, where DPP-4 is fully saturated, 70-80% of linagliptin was bound to other plasma proteins than DPP-4, hence 30-20% were unbound in plasma.
Vezava linagliptina na beljakovine v plazmi je odvisna od koncentracije in se zmanjša od približno 99 % pri 1 nmol/l na 75 do 89 % pri ≥ 30 nmol/l, kar priča o zasičenosti vezave na DPP-4 pri večanju koncentracije linagliptina.Pri velikih koncentracijah, pri katerih je DPP-4 povsem zasičen, se je 70 do 80 % linagliptina vezalo še na druge beljakovine v plazmi poleg DPP-4, zato ga je bilo 30 do 20 % nevezanega v plazmi.
Plasma protein binding of naloxegol in humans was low and the fraction unbound ranged from 80% to 100%.
Vezava naloksegola na beljakovine v plazmi je pri človeku majhna in nevezani delež sega od 80 do 100 %.
Plasma protein binding of rosiglitazone is high (approximately 99.8%) and is not influenced by concentration
Stopnja vezave rosiglitazona na plazemske proteine je zelo visoka (približno 99,8 %) in nanjo ne vplivata koncentracija zdravila ali bolnikova starost.
Plasma protein binding of rosiglitazone is high (approximately 99.8%) and is not influenced by concentration or age.
Vezava rosiglitazona na beljakovine v plazmi je visoka (približno 99,8 %) in koncentracija ali starost nanjo ne vplivata.
Plasma protein binding of safinamide is 88-90%.
Vezava safinamida na proteine v plazmi je 88–90 %.
Plasma protein binding studies in vitro indicate that abacavir binds only low to moderately (~49%) to human plasma proteins at therapeutic concentrations.
Študije vezave na plazemske proteine in vitro kažejo, da se abakavir pri terapevtskih koncentracijah le v manjši ali zmerni meri (~49%) veže na humane plazemske proteine.
Plasma protein binding was determined in vitro and calculated at ≥99.9%.
Vezava na plazemske proteine je bila določena in vitro in je izračunana pri ≥99.9%.
Plasma protein binding was low, approximately 40%.
Vezava na beljakovine plaze je nizka, le okoli
Plasma protein binding was low, approximately 40%.
Vezava na beljakovine plaze je nizka, le okoli 40%.
Plasma protein binding was low, approximately 40%.The volume of distribution at steady-state (Vss) determined after intravenous administration was 13.2 L/kg.
Volumen distribucije v fazi stabilizacije koncentracije (VSS), določen po intravenoznem vnosu je 13,2 L/kg.
Plasma S-(-) verapamil Cmax and AUC were both increased 1.5-fold, and tmax was decreased 24%.
Cmax in AUC S-(-) verapamila v plazmi se zvečata za 1,5-krat, tmax se zmanjša za 24 %.
Plasma salicylate concentrations above 300 mg/l (1.67 mmol/l) suggest intoxication.
Koncentracija salicilata v plazmi nad 300 mg/l (1,67 mmol/l) nakazuje zastrupitev.
Plasma samples should immediately be prepared by centrifugation in a pre-cooled centrifuge (4°C).
Vzorce plazme morate takoj pripraviti s centrifugiranjem v hlajeni centrifugi (4 °C).
Plasma samples were obtained out to 56 days (patients) or 36 days (volunteers) post-injection.
Krvne vzorce so dobili do 56 dni (bolniki) ali 36 dni (prostovoljci) po injiciranju.
Plasma triglycerides increased
Zvišane vrednosti plazemskega holesterola Zvišane vrednosti plazemskih trigliceridov
Plasma trough
V primeru uporabe skupaj z
Plasma trough concentrations of boceprevir were decreased when administered with an NNRTI with a similar metabolic pathway as nevirapine.
Najmanjša koncentracija boceprevirjapred naslednjim odmerkom se je zmanjšala, če so ga dajali z NNRTI, ki ima podobno presnovno pot kot nevirapin.
Plasma trough concentrations of boceprevir were decreased when administered with efavirenz.
Pri sočasni uporabi efavirenza in